Pegvisomant
- TRADE NAME: Somavert (Pfizer)
- INDICATIONS: Acromegaly
- CLASS: Growth hormone analog
- HALF-LIFE: 6 days
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Acarbose, Exenatide, Hydromorphone, Insulin, Latex, Metformin, Opioids, Oral hypoglycemics, Tapentadol
PREGNANCY CATEGORY: B
Please login to see the rest of this drug profile
SKIN
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
LOCAL
OTHER
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life Threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric